Evaluating Retention Rates in a Medication-Assisted Treatment Program

Only a few medications are available for the treatment of opioid use disorder (OUD), and few data exist regarding which medication is more likely to increase retention in a substance use treatment program. Findings from a retrospective review of an opioid use treatment program revealed an increase in retention rates for those receiving injectable buprenorphine extended-release (Sublocade) over those receiving transmucosal buprenorphine tablets/films (Suboxone). Because fatal opioid overdoses now lead the United States in injury-related deaths, it is imperative to provide data to health care providers that can help guide effective prescribing to save lives. (c) 2020 Elsevier Inc. All rights reserved.